CLL risk stratification: Role of genetic mutation

World Conference on Haematology & Medical Oncology

May 28-29, 2018 Osaka, Japan

Salah Aref

Mansoura University, Egypt

Keynote: J Cancer Sci Ther

Abstract :

Chronic Lymphocytic Leukemia (CLL) is clonal B cell neoplasm, most frequent in the old age. The clinical course is very heterogenous with the survival time ranging from months to decade. Recently, it was appeared that underlying this heterogeneity are genetic mutation disease progress. In recent years, the development of target therapy necessitates the determination of these generic mutations to tailor the therapy for each patient. In this presentation, we give spotlight on the genetic mutations in CLL and its role in affecting the patient course and treatment.

Biography :

Salah Aref is currently working as a Professor of Hematology in Mansoura University, Egypt and Director of Mansoura University Oncology Center laboratories. He is also working as a Member in National Board for promotion of professors in hematology. He has published more than 60 papers in the field of hemato-oncology. He has received many awards from Egyptian National Academy of Science, Mansoura University and International Society of Laboratory Hematology. He is acting as an Editorial Board Member and Peer Reviewer of many peer reviewed international journals and authored many books.
Email:salaharef@yahoo.com